| scholarly article | Q13442814 |
| P50 | author | Stuart E Turvey | Q45358108 |
| Shan-Yu Fung | Q45734728 | ||
| Hong Yang | Q57164247 | ||
| P2093 | author name string | Qiang Li | |
| Aihua Bao | |||
| P2860 | cites work | Toll-like receptor signalling | Q24570126 |
| Innate immunity in cystic fibrosis lung disease | Q27003347 | ||
| Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis | Q28254097 | ||
| Activation of the STING adaptor attenuates experimental autoimmune encephalitis. | Q33861332 | ||
| Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles | Q34023451 | ||
| Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist | Q34531671 | ||
| Toll-like receptors and Type I interferons | Q34613816 | ||
| Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration | Q34634591 | ||
| Toll-like receptors in systemic lupus erythematosus: potential for personalized treatment. | Q34650870 | ||
| Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies | Q34726541 | ||
| Unbiased screening of marine sponge extracts for anti-inflammatory agents combined with chemical genomics identifies girolline as an inhibitor of protein synthesis | Q35211600 | ||
| Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells | Q35949475 | ||
| Toll-like receptor signaling in primary immune deficiencies | Q36238886 | ||
| Role of Toll-like receptors in the development of sepsis | Q37085653 | ||
| TLRs and innate immunity | Q37100710 | ||
| Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. | Q37114768 | ||
| Principles of nanoparticle design for overcoming biological barriers to drug delivery | Q37162182 | ||
| Pattern recognition receptors and control of adaptive immunity | Q37361471 | ||
| Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles | Q37476252 | ||
| Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. | Q37497786 | ||
| The role of toll-like receptors in chronic inflammation | Q37616733 | ||
| TLRs and chronic inflammation. | Q37617730 | ||
| Targeting Toll-like receptors: emerging therapeutics? | Q37727910 | ||
| Targeting of Toll-like receptors: a decade of progress in combating infectious diseases | Q37896347 | ||
| The role of antimalarial agents in the treatment of SLE and lupus nephritis | Q37947108 | ||
| Assembly and localization of Toll-like receptor signalling complexes. | Q38233769 | ||
| Toll-like receptor signaling pathways | Q38259564 | ||
| Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial | Q38316900 | ||
| Toll-Like Receptor Pathways in Autoimmune Diseases | Q38357504 | ||
| Enhancing the pharmacokinetic/pharmacodynamic properties of therapeutic nucleotides using lipid nanoparticle systems | Q38591825 | ||
| Amino Acid-Dependent Attenuation of Toll-like Receptor Signaling by Peptide-Gold Nanoparticle Hybrids | Q38862975 | ||
| Design of Polyelectrolyte Multilayers to Promote Immunological Tolerance. | Q39436189 | ||
| Programming the cellular uptake of physiologically stable peptide-gold nanoparticle hybrids with single amino acids. | Q39467890 | ||
| Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines | Q39577031 | ||
| TLR5 as an anti-inflammatory target and modifier gene in cystic fibrosis | Q39633369 | ||
| Synthetic high-density lipoprotein-like nanoparticles potently inhibit cell signaling and production of inflammatory mediators induced by lipopolysaccharide binding Toll-like receptor 4. | Q39722614 | ||
| Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles | Q39742676 | ||
| Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers | Q39955953 | ||
| Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers | Q46225074 | ||
| Polyplexes assembled from self-peptides and regulatory nucleic acids blunt toll-like receptor signaling to combat autoimmunity. | Q48016268 | ||
| Endosomal pH modulation by peptide-gold nanoparticle hybrids enables potent anti-inflammatory activity in phagocytic immune cells. | Q51406548 | ||
| Increased expression of toll-like receptor-2 and -4 on leukocytes from patients with sepsis | Q80873411 | ||
| P433 | issue | 125 | |
| P921 | main subject | toll-like receptor | Q408004 |
| P577 | publication date | 2017-07-26 | |
| P1433 | published in | Journal of Visualized Experiments | Q954500 |
| P1476 | title | Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling |
| Q89891141 | Manipulation of macrophage polarization by peptide-coated gold nanoparticles and its protective effects on acute lung injury | cites work | P2860 |
Search more.